Skip to main content

Table 4 Details for rituximab and chemotherapy regimens used during overall treatment

From: Post-transplant lymphoproliferative disorder (PTLD): single institutional experience of 141 patients

Therapy type

Sub-type

As 1st line therapy

As 2nd line therapy

As 3rd line therapy

n

%

n

%

n

%

Rituximab alone

 

35

24.8

4

2.8

2

1.4

Chemotherapy (+ R)

R-chop

22

15.6

11

7.8

2

1.4

R/C (cyclophosphamide)

20

14.2

5

3.5

  

R-EPOCH

2

1.4

    

R-CVP

4

2.8

2

1.4

1

0.7

BR

1

0.7

1

0.7

  

R-hyperCVAD

1

0.7

    

RICE

1

0.7

1

0.7

  

R-Mtx

1

0.7

    

Chemotherapy (− R)

CHOP

5

3.5

1

0.7

  

ABVD

1

0.7

1

0.7

  

CVP

1

0.7

1

0.7

  

CEOP

1

0.7

    

Other regimens

5

3.5

12

8.5

8

5.7